At Least 50% of Recent Onset Rheumatoid Arthritis Patients Become Free of Signs and Symptoms Within 36 WeeksThe results of a systematic step-up DMARD treatment schedule in combination with tight control
PARIS, France, Wednesday June 11th 2008: At least 50% of recent onset rheumatoid arthritis patients achieve remission (a state free of signs and symptoms) within 36 weeks when following a systematic approach of step-up DMARD treatment in combination with tight control, according to results of a study presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. Results of this study indicate that achieving remission is not only possible during clinical trials but can be a realistic goal of standard clinical care.
Of 169 early RA patients, remission (defined as
DAS28<2.6) was achieved in 15.5% at week 8 (23/148), 22.2% at
week 12 (24/108), 30.7 at week 20 (23/75), 38.8% at week 24
(33/85), 52.1% at week 36 (38/73) and 51% at week 48-52
The researchers achieved these results through implementation of a tightly regulated DMARD treatment scheme, as follows:
As part of the Dutch Rheumatoid Arthritis Monitoring Registry (DREAM), investigators performed a prospective descriptive study of a cohort of recent onset rheumatoid arthritis DMARD-naïve, patients in daily clinical practice, between January 2006 and January 2008. 190 consecutive patients with recently diagnosed RA under the care of the rheumatology clinics of three hospitals in the Netherlands were included. Results were taken from the first 169 patients with DAS28>3.2 at inclusion.
At baseline, patient characteristics between the hospitals were comparable – average patient age was 57.3 years (13.7), 63.9% were female, 52.7% of which were rheumatoid factor positive, with an average disease duration of 16 weeks (1-52), ESR 33.2 (20.5), CRP 23.5 (26.4), DAS28 5.1 (1.1), HAQ 1.3 (0.6).
For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress press office on:
Rory Berrie: Onsite tel: +44 (0) 7789 270 392
Camilla Dormer: Onsite tel: +44 (0) 7876 190 439
Abstract number: OP-0003
About EULARThe European League Against Rheumatism (EULAR) is the organisation which represents the patient, health professional and scientific societies of rheumatology of all the European nations. The aims of EULAR are to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with musculoskeletal diseases by the governing bodies in Europe. Diseases of bones and joints, such as rheumatoid arthritis and osteoarthritis cause disability in 4 - 5 % of the adult population and are predicted to rise as people live longer. As new treatments emerge and cellular mechanisms are discovered, EULAR 2008 brings together more than 12,000 experts - scientists, clinicians, healthcare workers, pharmaceutical companies and patients - to share their knowledge in a global endeavour to challenge the pain and disability caused by musculo-skeletal disorders. To find out more information about the activities of EULAR, visit: www.eular.org
Posted: June 2008